Psyence Biomedical announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context has been listed on the Australian New Zealand Clinical Trials Registry, under registration number 12624000449538p. The randomized, double-blind, placebo-controlled Phase IIb study will test three doses of nature-derived psilocybin in 84 patients in conjunction with psychotherapy. Psyence Biomed anticipates enrolling the first subject in the second quarter of 2024 and expects the primary endpoint results to be available in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBM:
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
- Psyence Biomedical partners with Fluence, iNGENu to train research therapists
- Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
- Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
- Psyence Group closes strategic restructuring on non-clinical business
